Circ will be responsible for development and commercialization.

IntelGenx and Circ Pharma formed a partnership in which IntelGenx will formulate, manufacture, and supply to Circ, and Circ will develop and commercialize, a novel drug product for the treatment of hyperlipidemia. Under the terms of the agreement, Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product’s sales. IntelGenx will use its Versatab technology to formulate the product.

This is the first product in a series of Circ Pharma’s controlled release lipid lowering agents specifically designed to target the absorption of a drug in order to reduce the effective dose and potentially lower the side effects. The product is expected to reach the market in 2012.


Previous articleResearchers Find Proteins Key to the Spread of Malaria
Next articleFAK Signaling Required for Ras- and PI3K-Dependent Breast Tumorigenesis